Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ROIV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
7 hours ago
seekingalpha.com
9 hours ago
zacks.com
9 hours ago
seekingalpha.com
12 hours ago
fool.com
16 hours ago
fool.com
18 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
NA
vs NA
Q4.23
N/A
-0.21
vs -0.49
Q1.24
N/A
-0.23
vs -0.20
Q2.24
N/A
-0.18
vs -0.38
Q3.24
N/A
-0.29
vs -0.26
Q4.24
N/A
-0.13
vs -0.21
Q1.25
N/A
-0.22
vs -0.23
Q2.25
N/A
-0.18
vs -0.18
Q3.25
N/A
-0.31
vs -0.29
Q4.25
N/A
-0.31
vs -0.13
Sales Growth
YoY
Current
Estimates
Q3.23
NA
NA vs NA
Q4.23
+118%
37.1M vs 17.1M
Q1.24
+6%
28.9M vs 27.4M
Q2.24
+155%
55.1M vs 21.6M
Q3.24
-88%
4.5M vs 37.1M
Q4.24
-76%
9M vs 37.1M
Q1.25
-74%
7.6M vs 28.9M
Q2.25
-96%
2.2M vs 55.1M
Q3.25
+41%
6.3M vs 4.5M
Q4.25
-28%
6.5M vs 9M
Return on Equity
QoQ
Q1.23
-3%
-0.03
vs -0.37
Q2.23
-32%
-0.32
vs -0.03
Q3.23
-32%
-0.32
vs -0.32
Q4.23
+84%
0.84
vs -0.32
Q1.24
-3%
-0.03
vs 0.84
Q2.24
+2%
0.02
vs -0.03
Q3.24
-4%
-0.04
vs 0.02
Q4.24
+3%
0.03
vs -0.04
Q1.25
-4%
-0.04
vs 0.03
Q2.25
-5%
-0.05
vs -0.04
Institutionnal Ownership
QoQ
Q4.22
116
116
vs 82
41%
Q1.23
154
154
vs 116
33%
Q2.23
187
187
vs 154
21%
Q3.23
218
218
vs 187
17%
Q4.23
241
241
vs 218
11%
Q1.24
269
269
vs 241
12%
Q2.24
307
307
vs 269
14%
Q3.24
309
309
vs 307
1%
Q4.24
328
328
vs 309
6%
Q1.25
323
323
vs 328
-2%
Quote Panel
Key Metrics
Forecast
935%2026-Revenue
-271%2026-EPS
95%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Cantor Fitzgerald
initialisePrevious: Not converted
2022-04-29
Now: Overweight
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
NASDAQ
Unprofitable
Unprofitable
-0.05Â ( -0.42%)
Pre-market 11.84$0.07 (0.64%)
Relative Strenght
60
Volume Buzz
-42%
Earning Acce
No
Dist 52w H.
10%Relative Strength
ROIV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|